Data / Drug companies / GLP-1 Receptor Agonist
GLP-1 Receptor Agonist drugs: 9 drugs from 15 companies in the FDA NDC directory
GLP-1 Receptor Agonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 123 products in this class from 15 companies, covering 9 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on April 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 15Companies
- 123Products
- 9Drugs by generic name
Drugs in the GLP-1 Receptor Agonist class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Liraglutide | 22 | 11 |
| Tirzepatide | 54 | 2 |
| Semaglutide | 18 | 2 |
| Dulaglutide | 11 | 2 |
| Exenatide | 4 | 2 |
| Oral semaglutide | 6 | 1 |
| Orforglipron | 6 | 1 |
| Insulin degludec and liraglutide | 1 | 1 |
| Insulin glargine and lixisenatide | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Eli Lilly and Company | 58 | injection, solution; tablet, film coated | New drug applications (NDA) | April 1, 2026 |
| Novo Nordisk | 23 | injection, solution; tablet | New drug applications (NDA) | April 27, 2026 |
| A-S Medication Solutions | 22 | injection, solution; injection | New drug applications (NDA) | January 22, 2026 |
| Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 3 | injection, solution | Generic drugs (ANDA) | December 24, 2024 |
| Amneal Pharmaceuticals LLC | 2 | injection | Generic drugs (ANDA) | November 22, 2024 |
| AstraZeneca Pharmaceuticals LP | 2 | injection | New drug applications (NDA) | December 12, 2014 |
| Biocon Pharma Inc. | 2 | injection, solution; injection | Generic drugs (ANDA) | April 25, 2026 |
| Cipla USA Inc. | 2 | injection, solution | Generic drugs (ANDA) | February 25, 2026 |
| Orbicular Pharmaceutical Technologies Private Limited | 2 | injection, solution | Generic drugs (ANDA) | February 26, 2026 |
| Teva Pharmaceuticals, Inc. | 2 | injection, solution; injection | Generic drugs (ANDA) | August 28, 2025 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection | Generic drugs (ANDA) | December 24, 2024 |
| Lupin Pharmaceuticals, Inc. | 1 | injection | Generic drugs (ANDA) | October 2, 2025 |
| Meitheal Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | April 2, 2025 |
| NorthStar RxLLC | 1 | injection | Generic drugs (ANDA) | March 1, 2026 |
| Sanofi-Aventis U.S. LLC | 1 | injection, solution | Biologics (BLA) | November 21, 2016 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 93 | 75.6% |
| Injection | 14 | 11.4% |
| Tablet | 10 | 8.1% |
| Tablet, film coated | 6 | 4.9% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.